Through integrative studies, including CRISPR-Cas9i screening across various prostate cancer cell models, analysis of clinical cancer-specific expression, relevance to patient prognosis, and in vitro loss-of-function validation, we identified three cancer-specific targets: CDC20, RRM2, and DTL. Here, RRM2 is linked to prostate carcinoma.